Steven Joniau
Pulmonary and Respiratory Medicine · 2009–2018
A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 224 citations into it
- Oncology — 79 citations into it
Whom Steven Joniau trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- A. Billis (in Pulmonary and Respiratory Medicine)
Papers from Steven Joniau's perspective
Ordered by how strongly the researchers Steven Joniau trusts endorse each paper. Same corpus, a different order for every researcher.
- Screening and prostate-cancer mortality in a randomized European study. (New England Journal of Medicine)
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
- Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. (Journal of Clinical Oncology)
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (New England Journal of Medicine)
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer (New England Journal of Medicine)
- Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
- International variation in prostate cancer incidence and mortality rates. (European Urology)
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (The Lancet)
- Comparative effectiveness of minimally invasive vs open radical prostatectomy. (Journal of the American Medical Association (JAMA))
Their papers
- Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) — 797 citations
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017) — 1,488 citations
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017) — 2,938 citations
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. (2017) — 1,115 citations
- EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014) — 2,039 citations
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2014) — 712 citations
- Guidelines on Prostate Cancer (2013) — 955 citations
- [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. (2011) — 883 citations
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2011) — 1,175 citations
- EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. (2011) — 1,458 citations
- [EAU guidelines on prostate cancer]. (2009) — 1,510 citations